These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38441212)

  • 1. Mild-to-moderate COVID-19 does not predispose to the development of autoimmune rheumatic diseases or autoimmune-based thrombosis.
    Kozłowski P; Lulek M; Skwarek A; Śmiarowski M; Małecka-Giełdowska M; Ciepiela O
    Scand J Immunol; 2023 Nov; 98(5):e13313. PubMed ID: 38441212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of systemic autoimmune rheumatic diseases and clinical significance of ANA profile: data from a tertiary hospital in Shanghai, China.
    Yang Z; Ren Y; Liu D; Lin F; Liang Y
    APMIS; 2016 Sep; 124(9):805-11. PubMed ID: 27328803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison study of bead-based and line-blot multiplex ANA immunoassays in the diagnosis of systemic autoimmune rheumatic diseases.
    Yuan W; Cao H; Li W; Wu X; Zheng J
    Clin Rheumatol; 2022 Mar; 41(3):899-909. PubMed ID: 34626262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with the antinuclear antibody (ANA) titer of systemic autoimmune rheumatic diseases in ANA-positive patients after treatment: a retrospective study.
    Xiao Y; Lin Y; Zhang Y; Wang J; Zeng Y
    Clin Exp Med; 2022 Aug; 22(3):439-446. PubMed ID: 34542782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies Against DFS70/LEDGF Exclusion Markers for Systemic Autoimmune Rheumatic Diseases (SARD).
    Seelig CA; Bauer O; Seelig HP
    Clin Lab; 2016; 62(4):499-517. PubMed ID: 27215068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 infection as a trigger of autoimmune response.
    Sacchi MC; Tamiazzo S; Stobbione P; Agatea L; De Gaspari P; Stecca A; Lauritano EC; Roveta A; Tozzoli R; Guaschino R; Bonometti R
    Clin Transl Sci; 2021 May; 14(3):898-907. PubMed ID: 33306235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases.
    Strassburg CP; Alex B; Zindy F; Gerken G; Lüttig B; Meyer zum Büschenfelde KH; Bréchot C; Manns MP
    J Hepatol; 1996 Dec; 25(6):859-66. PubMed ID: 9007714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence of an interferon signature in individuals who are anti-nuclear antibody positive lacking a systemic autoimmune rheumatic disease diagnosis.
    Wither J; Johnson SR; Liu T; Noamani B; Bonilla D; Lisnevskaia L; Silverman E; Bookman A; Landolt-Marticorena C
    Arthritis Res Ther; 2017 Feb; 19(1):41. PubMed ID: 28245862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antinuclear antibodies (ANAs) detected by indirect immunofluorescence (IIF) method in acute COVID-19 infection; future roadmap for laboratory diagnosis.
    Peker BO; Şener AG; Kaptan Aydoğmuş F
    J Immunol Methods; 2021 Dec; 499():113174. PubMed ID: 34737165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome.
    Andreoli L; Chighizola CB; Nalli C; Gerosa M; Borghi MO; Pregnolato F; Grossi C; Zanola A; Allegri F; Norman GL; Mahler M; Meroni PL; Tincani A
    Arthritis Rheumatol; 2015 May; 67(8):2196-204. PubMed ID: 25939498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of specific antinuclear antibodies in dogs using a line immunoassay and enzyme-linked immunosorbent assay.
    Bremer HD; Lattwein E; Renneker S; Lilliehöök I; Rönnelid J; Hansson-Hamlin H
    Vet Immunol Immunopathol; 2015 Dec; 168(3-4):233-41. PubMed ID: 26547884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antinuclear antibodies in the diagnostics of rheumatic diseases].
    Rose T; Dörner T
    Z Rheumatol; 2020 Jun; 79(5):447-458. PubMed ID: 32458159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Evaluation of ELISA and Chemiluminescent Assays as Alternative Screening Tests to Indirect Immunofluorescence for the Detection of Antibodies to Cellular Antigens.
    de Almeida Brito F; Maria Elói Santos S; Aparecida Ferreira G; Pedrosa W; Gradisse J; Cristina Costa L; Pretti Figueiredo Neves S
    Am J Clin Pathol; 2016 Mar; 145(3):323-31. PubMed ID: 27124914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is COVID-19 severity unrelated to antinuclear antibodies?
    Vahabi M; Mirsharif ES; Ghazanfari T
    Transpl Immunol; 2023 Jun; 78():101791. PubMed ID: 36682573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Algorithm for antinuclear antibodies in subjects with clinical suspicion of autoimmune diseases.
    Naranjo L; Shovman O; Pérez D; Infantino M; Cabrera-Marante O; Lozano F; Gilburd B; Manfredi M; Serrano M; Morillas L; Shoenfeld Y; Serrano A
    Clin Exp Rheumatol; 2020; 38(4):633-639. PubMed ID: 31694754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment.
    Shah S; Danda D; Kavadichanda C; Das S; Adarsh MB; Negi VS
    Rheumatol Int; 2020 Oct; 40(10):1539-1554. PubMed ID: 32666137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic.
    Sjöwall J; Azharuddin M; Frodlund M; Zhang Y; Sandner L; Dahle C; Hinkula J; Sjöwall C
    Front Immunol; 2021; 12():724047. PubMed ID: 34512651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of detecting anti-DFS70 in routine clinical practice: comparison of different care settings.
    Bonroy C; Schouwers S; Berth M; Stubbe M; Piette Y; Hoffman I; Devreese K; Van Hoovels L
    Clin Chem Lab Med; 2018 Jun; 56(7):1090-1099. PubMed ID: 29427547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence of anti-nuclear antibodies alone is associated with changes in B cell activation and T follicular helper cells similar to those in systemic autoimmune rheumatic disease.
    Baglaenko Y; Chang NH; Johnson SR; Hafiz W; Manion K; Ferri D; Noamani B; Bonilla D; Rusta-Sellehy S; Lisnevskaia L; Silverman E; Bookman A; Landolt-Marticorena C; Wither J
    Arthritis Res Ther; 2018 Nov; 20(1):264. PubMed ID: 30486869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of anti-DFS70 for identifying antinuclear antibody-positive patients without systemic autoimmune rheumatic disease.
    Tan TC; Ng CYL; Leong KP
    Singapore Med J; 2022 Mar; 63(3):147-151. PubMed ID: 32798356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.